Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy
The potential of utilizing receptor-specific agents such as monoclonal antibodies (MAb), and MAb-derived smaller molecules, as carriers of radionuclides for the selective destruction of tumors has stimulated much research activity. The success of such applications depends on many factors, especially the tumor binding properties of the antibody reagent, the efficiency of labeling and in-vivo stability of the radioconjugate and, on the careful choice of the radionuclide best suited to treat the tumor under consideration. The radiolabeled antibody technique for radioimmunotherapy (RIT), however, has experienced many limitations, and its success has not matched the expectations that were raised more than a decade ago. The problems that have been identified include: (i) degradation of antibody immunoreactivity resulting from chemical manipulations required for labeling; (ii) lack of suitable radioisotopes and methods for stable attachment of the radiolabel; (iii) in-vivo instability of the radioimmunoconjugates; (iv) excessive accumulation of activity in non-target locations; and (v) lack of radioimmunoconjugate accessibility to cells internal to a tumor mass. A careful choice of the radionuclide(s) best suited to treat the tumor under consideration is one of the most important requirements for successful radioimmunotherapy. This study evaluates copper 67 and samarium 153 for tumor radioimmunotherapy.
- Research Organization:
- Brookhaven National Lab., Upton, NY (United States)
- Sponsoring Organization:
- USDOE, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 34290
- Report Number(s):
- BNL--61356; ON: DE95007297
- Country of Publication:
- United States
- Language:
- English
Similar Records
Improved radioimmunotherapy of hematologic malignancies
Criteria for the selection of radionuclides for tumor radioimmunotherapy
Improved radioimmunotherapy of hematologic malignancies. Progress report, 1988--1991
Technical Report
·
Fri May 12 00:00:00 EDT 1989
·
OSTI ID:5514112
Criteria for the selection of radionuclides for tumor radioimmunotherapy
Conference
·
Mon Dec 31 23:00:00 EST 1990
·
OSTI ID:5332217
Improved radioimmunotherapy of hematologic malignancies. Progress report, 1988--1991
Technical Report
·
Mon Dec 30 23:00:00 EST 1991
·
OSTI ID:10112383